MX363077B - Inhibidores de metastasis. - Google Patents
Inhibidores de metastasis.Info
- Publication number
- MX363077B MX363077B MX2015014036A MX2015014036A MX363077B MX 363077 B MX363077 B MX 363077B MX 2015014036 A MX2015014036 A MX 2015014036A MX 2015014036 A MX2015014036 A MX 2015014036A MX 363077 B MX363077 B MX 363077B
- Authority
- MX
- Mexico
- Prior art keywords
- metastasis
- inhibitors
- methods
- inhibiting
- cancers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un compuesto inhibidor de MACKS para usarse en la fabricación de un medicamento para inhibir la metástasis de células cancerosas, en donde el compuesto inhibidor de MARCKS es un péptido que tiene una secuencia de aminoácidos seleccionada del grupo consistente en la SEQ ID NO: 1 a la SEQ ID NO: 231, la SEQ ID NO: 234 y la SEQ ID NO: 235, estando modificado químicamente el aminoácido N-terminal y/o C-terminal de la secuencia peptídica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361808966P | 2013-04-05 | 2013-04-05 | |
PCT/US2014/033206 WO2014165853A1 (en) | 2013-04-05 | 2014-04-07 | Inhibitors of metastasis |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015014036A MX2015014036A (es) | 2016-02-25 |
MX363077B true MX363077B (es) | 2019-03-07 |
Family
ID=51654619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015014036A MX363077B (es) | 2013-04-05 | 2014-04-07 | Inhibidores de metastasis. |
Country Status (20)
Country | Link |
---|---|
US (4) | US9408886B2 (es) |
EP (1) | EP2981279B1 (es) |
JP (1) | JP6449849B2 (es) |
KR (1) | KR102191695B1 (es) |
CN (1) | CN105517562B (es) |
AU (1) | AU2014247979B2 (es) |
BR (1) | BR112015025398A2 (es) |
CA (1) | CA2908832C (es) |
DK (1) | DK2981279T3 (es) |
ES (1) | ES2714863T3 (es) |
HK (1) | HK1221159A1 (es) |
HU (1) | HUE043971T2 (es) |
IL (1) | IL241937B (es) |
MX (1) | MX363077B (es) |
PL (1) | PL2981279T3 (es) |
PT (1) | PT2981279T (es) |
RU (1) | RU2681213C2 (es) |
SG (2) | SG11201508249WA (es) |
WO (1) | WO2014165853A1 (es) |
ZA (1) | ZA201508010B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2714863T3 (es) | 2013-04-05 | 2019-05-30 | Biomarck Pharmaceuticals Ltd | Péptidos del inhibidor de MARCKS para la inhibición de metástasis |
CN108686220A (zh) * | 2018-07-13 | 2018-10-23 | 刘慧荣 | 一种针对甲状腺癌的抗肿瘤剂 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7544772B2 (en) | 2001-06-26 | 2009-06-09 | Biomarck Pharmaceuticals, Ltd. | Methods for regulating inflammatory mediators and peptides useful therein |
US8501911B2 (en) | 1999-02-24 | 2013-08-06 | Biomarck Pharmaceuticals, Ltd | Methods of reducing inflammation and mucus hypersecretion |
US7265088B1 (en) | 2000-02-24 | 2007-09-04 | North Carolina State University | Method and compositions for altering mucus secretion |
ATE519493T1 (de) | 2001-06-26 | 2011-08-15 | Univ North Carolina State | Blockierendes peptid für die sekretion von entzündungszellen |
AU2002362753B9 (en) * | 2001-10-05 | 2008-05-15 | The Trustees Of The University Of Pennsylvania | Compositions for and methods of treating and preventing sirs/sepsis |
DE60308251T2 (de) | 2002-04-17 | 2007-08-30 | Canon K.K. | Vorrichtung zur Bereitstellung von öffentlichen Schlüsselzertifikaten |
CN101146545B (zh) | 2005-01-20 | 2012-12-26 | 拜欧马克医药有限公司 | 基于mans的结构的粘蛋白分泌过多抑制剂和应用方法 |
WO2006086681A2 (en) | 2005-02-09 | 2006-08-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of inhibiting smooth muscle cell migration and proliferation |
CN103990111B (zh) * | 2006-07-26 | 2016-08-31 | 拜欧马克医药有限公司 | 减少炎症介质释放的方法和可用于该方法的肽 |
CA2664844A1 (en) | 2006-10-06 | 2008-10-23 | Celtaxsys, Inc. | Chemorepulsion of cells |
AU2007318115A1 (en) | 2006-10-27 | 2008-05-15 | George Mason Intellectual Properties, Inc. | Assay for metastatic colorectal cancer |
WO2009062128A2 (en) | 2007-11-08 | 2009-05-14 | Indiana University Research And Technology Corporation | Combination drug therapy for the treatment of cancer |
EP2105511A1 (en) * | 2008-03-28 | 2009-09-30 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung |
US9073974B2 (en) * | 2009-12-21 | 2015-07-07 | The Regents Of The University Of California | RGD-containing cyclic peptides |
EP2697386B1 (en) * | 2011-04-08 | 2017-11-01 | Tufts Medical Center, Inc. | Pepducin design and use |
ES2714863T3 (es) * | 2013-04-05 | 2019-05-30 | Biomarck Pharmaceuticals Ltd | Péptidos del inhibidor de MARCKS para la inhibición de metástasis |
-
2014
- 2014-04-07 ES ES14779844T patent/ES2714863T3/es active Active
- 2014-04-07 RU RU2015146997A patent/RU2681213C2/ru active
- 2014-04-07 CA CA2908832A patent/CA2908832C/en active Active
- 2014-04-07 EP EP14779844.1A patent/EP2981279B1/en active Active
- 2014-04-07 SG SG11201508249WA patent/SG11201508249WA/en unknown
- 2014-04-07 BR BR112015025398A patent/BR112015025398A2/pt not_active Application Discontinuation
- 2014-04-07 PT PT14779844T patent/PT2981279T/pt unknown
- 2014-04-07 CN CN201480031461.3A patent/CN105517562B/zh active Active
- 2014-04-07 JP JP2016506681A patent/JP6449849B2/ja active Active
- 2014-04-07 DK DK14779844.1T patent/DK2981279T3/en active
- 2014-04-07 WO PCT/US2014/033206 patent/WO2014165853A1/en active Application Filing
- 2014-04-07 MX MX2015014036A patent/MX363077B/es unknown
- 2014-04-07 KR KR1020157031658A patent/KR102191695B1/ko active IP Right Grant
- 2014-04-07 AU AU2014247979A patent/AU2014247979B2/en active Active
- 2014-04-07 SG SG10201708125PA patent/SG10201708125PA/en unknown
- 2014-04-07 PL PL14779844T patent/PL2981279T3/pl unknown
- 2014-04-07 US US14/246,864 patent/US9408886B2/en active Active
- 2014-04-07 HU HUE14779844A patent/HUE043971T2/hu unknown
-
2015
- 2015-10-06 IL IL241937A patent/IL241937B/en active IP Right Grant
- 2015-10-28 ZA ZA2015/08010A patent/ZA201508010B/en unknown
-
2016
- 2016-07-06 US US15/203,376 patent/US10011636B2/en active Active
- 2016-08-04 HK HK16109310.6A patent/HK1221159A1/zh unknown
-
2018
- 2018-06-04 US US15/996,797 patent/US10683328B2/en active Active
-
2020
- 2020-06-12 US US16/900,130 patent/US11466054B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017502141A1 (en) | Compounds and their methods of use | |
HK1252149A1 (zh) | 使用pd-l1亞型識別、評估、預防和治療癌症的組合物和方法 | |
PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
PH12017501999A1 (en) | K-ras modulators | |
MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
MX2016007801A (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
WO2014164704A3 (en) | Compounds and compositions for the treatment of cancer | |
MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
PH12015501997A1 (en) | Compositions and methods for diagnosis and treatment of hepatic cancers | |
PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
EP3085380A4 (en) | Composition for treating prostate cancer | |
MY180834A (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
PH12017501879A1 (en) | Methods for treating cancer | |
PH12015501038A1 (en) | Inhibitors of iap | |
MX2015013021A (es) | 5-bromo-indirrubinas. | |
MX2016016507A (es) | Composiciones y metodos para tratar canceres. | |
MX2021006326A (es) | Inhibidores de pcna. | |
WO2012170742A3 (en) | Treatment and prevention of cancer with hmgb1 antagonists | |
MX2015007608A (es) | Metodos y composiciones para inhibir cnksr1. | |
MX2015014036A (es) | Inhibidores de metastasis. |